Article Exclusion List with Reason for Exclusion
| Author, Year | Title | Reason for Exclusion |
|---|---|---|
| Abramson MA, 2002 |
Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Primary Bacteremia: At What Costs? | Does not pertain to calculated attributable CLABSI cost estimates |
| Al-Rawajfah OM, 2009 |
Incidence of and risk factors for nosocomial bloodstream infections in adults in the United States. | Does not pertain to calculated attributable CLABSI cost estimates |
| Armour AD, 2007 |
The impact of nosocomially-acquired resistant Pseudomonas aeruginosa infection in a burn unit. | Does not pertain to calculated attributable CLABSI cost estimates |
| Arnow PM, 1993 |
Consequences of intravascular catheter sepsis. | Published before 2002 |
| Ben-David D, 2009 |
Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? | Compares and/or combines CLABSI cost estimates with other HAI |
| Berenholtz SM, 2004 |
Eliminating catheter-related bloodstream infections in the intensive care unit. | Does not pertain to calculated attributable CLABSI cost estimates |
| Blot S, 2002 |
Clinical impact of nosocomial Klebsiella bacteremia in critically ill patients. | Does not pertain to calculated attributable CLABSI cost estimates |
| Blot S, 2005 |
Clinical and economic outcomes in critically ill patients with nosocomial catheterrelated bloodstream infection. | Pertains to hospital(s) not within the United States |
| Blot S, 2002 |
Effects of nosocomial candidemia on outcomes of critically ill patients. | Does not pertain to calculated attributable CLABSI cost estimates |
| Blot S, 2003 |
Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. | Does not pertain to calculated attributable CLABSI cost estimates |
| Blot S, 2003 |
Evaluation of outcome in critically ill patients with nosocomial enterobacter bacteremia: results of a matched cohort study. | Does not pertain to calculated attributable CLABSI cost estimates |
| Blot S, 2003 |
Nosocomial bacteremia involving Acinetobacterbaumannii in critically ill patients: a matched cohort study. | Does not pertain to calculated attributable CLABSI cost estimates |
| Blot S, 2002 |
Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: Clinical outcome and length of hospitalization. | Does not pertain to calculated attributable CLABSI cost estimates |
| Borschel DM, 2006 |
Are antiseptic-coated central venous catheters effective in a real-world setting? | Does not pertain to calculated attributable CLABSI cost estimates |
| Brun-Buisson C, 2003 |
The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. | Cost estimates not in U.S. dollars |
| Burke JP, 2003 |
Infection control—a problem for patient safety. | Does not pertain to calculated attributable CLABSI cost estimates |
| Burton DC, 2009 |
Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. | Does not pertain to calculated attributable CLABSI cost estimates |
| Carbon C 1999 |
Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. | Published before 2002 |
| Carmeli Y, 2002 | Health and economic outcomes of vancomyecin resistant enterococci. | Does not pertain to CLABSI specific HAI |
| CDC, 2005 |
Reduction in central line-associated bloodstream infections among patients in intensive care units—Pennsylvania, April 2001-March 2005 | Does not pertain to calculated attributable CLABSI cost estimates |
| CDC, 1992 |
Public health focus: surveillance, prevention, and control of nosocomial infections. | Published before 2002 |
| CDC, 1998 |
National Nosocomial Infections Surveillance (NNIS) system report, data summary from October 1986- April 1998 | Published before 2002 |
| CDC, 2011 |
Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009. | Does not pertain to calculated attributable CLABSI cost estimates |
| Coopersmith CM, 2002 |
Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. | Does not pertain to calculated attributable CLABSI cost estimates |
| Correa L, 2000 |
Problems and solutions in hospital-acquired bacteraemia. | Published before 2002 |
| Cosgrove SE, 2006 |
Evidence that prevention makes cents: Costs of catheter-associated bloodstream infections in the intensive care unit. | Does not pertain to calculated attributable CLABSI cost estimates |
| Cosgrove SE, 2005 |
The impact of methicillin resistance in Staphylococcus Aureusbacterimia on patient outcomes: mortality, length of stay, and hospital charges. | Compares and/or combines CLABSI cost estimates with other HAI |
| Crawford AG, 2004 |
Cost-benefit analysis of chlorhexidinegluconate dressing in the prevention of catheter-related bloodstream infections. | Does not pertain to calculated attributable CLABSI cost estimates |
| Curtis LT 2008 |
Prevention of hospital-acquired infections: review of non-pharmacological interventions. | Review, meta-analysis and systematic review articles |
| DiazGranados CA, 2005 |
Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. | Review, meta-analysis and systematic review articles |
| Digiovine B, 1999 |
The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. | Published before 2002 |
| Dimick JB, 2001 |
Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. | Published before 2002 |
| Dimick JB, 2001 |
Intersive care unit physician staffing is associated with decreased length of stay, hospital cost, and complications after espothageal resection. | Published before 2002 |
| Dixon RE, 1987 |
Costs of nosocomial infections and benefits of infection control programs. In: Wenzel RP, ed. Prevention and Control of Nosocomial Infections, 1st ed. | Published before 2002 |
| Donowitz LG, 1987 |
Neonatal intensive care unit bacteremia: emergence of gram-positive bacteria as major pathogens. | Published before 2002 |
| Edmond MB, 1999 |
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. | Published before 2002 |
| Engemann JJ, 2003 | Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcusaureus surgical site infection. | Does not pertain to CLABSI specific HAI |
| Esatoglu AE, 2006 |
Additional cost of hospital-acquired infections to the patient: a case study in Turkey. | Pertains to hospital(s) not within the United States |
| Evans RS, 1998 |
A computer-assisted management program for antibiotics and other anti-infective agents. | Published before 2002 |
| Falagas ME, 2006 |
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. | Review, meta-analysis and systematic review articles |
| Fraher MH, 2009 |
Cost-effectiveness of employing a total parenteral nutrition surveillance nurse for the prevention of catheter-related bloodstream infections. | Pertains to hospital(s) not within the United States |
| Fukuda H, 2011 |
Variations in analytical methodology for estimating costs of hospital-acquired infections: a systematic review. | Review, meta-analysis and systematic review articles |
| Gagne JJ, 2006 |
Costs associated with candidemia in a hospital setting. | Does not pertain to CLABSI specific HAI |
| Garrouste-Orgeas M, 2000 |
A one-year prospective study of nosocomial bacteremia in ICU and non-ICU patients and its impact on patient outcome. | Published before 2002 |
| GianinoMS, 1993 |
The impact of a nutritional support team on the cost and management of multilumen central venous catheters. | Published before 2002 |
| Goldstein M, 2000 |
The medical and financial costs associated with termination of a nutrition support nurse. | Published before 2002 |
| Gonzales RD, 2001 |
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. | Published before 2002 |
| Graves N, 2007 |
Effect of healthcare-acquired infection on length of hospital stay and cost. | Pertains to hospital(s) not within the United States |
| Graves N, 2005 |
Correcting for bias when estimating the cost of hospital-acquired infection: an analysis of lower respiratory tract infections in non-surgical patients. | Pertains to hospital(s) not within the United States |
| Graves N, 2007 |
Economics and preventing hospital acquired infection–broadening the perspective. | Simulated cost model |
| Gudlaugsson O, 2003 |
Attributable mortality of nosocomial candidemia, revisited. | Does not pertain to calculated attributable CLABSI cost estimates |
| Haley RW, 1991 |
Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. | Published before 2002 |
| Haley RW, 1985 |
The nationwide nosocomial infection rate: a new need for vital statistics. | Published before 2002 |
| Haley RW, 1985 |
The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. | Published before 2002 |
| Haley RW, 1998 |
Cost-benefit analysis of infection control activities. | Published before 2002 |
| Haley RW, 1987 | The financial incentive for hospitals to prevent nosocomial infections under the prospective payment system: an empirical determination from a nationally representative sample. | Published before 2002 |
| Halton K, 2007 |
Economic evaluation and catheter-related bloodstream infections. | Review, meta-analysis and systematic review articles |
| Heiselman D, 1994 |
Nosocomial bloodstream infections in the critically ill. | Published before 2002 |
| Herwaldt LA, 2006 |
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. | Does not pertain to calculated attributable CLABSI cost estimates |
| Higuera F, 2007 |
Attributable cost and length of stay for patients with central venous catheter-associated bloodstream infection in Mexico City intensive care units: a prospective, matched analysis. | Pertains to hospital(s) not within the United States |
| Hollenbeak CS 2011 |
The cost of catheter-related bloodstream infections: implications for the value of prevention. | Article not peer reviewed |
| Hollenbeak CS 2002 |
Nonrandom selection and the attributable cost of surgical-site infections. | Does not pertain to CLABSI specific HAI |
| Hoste EA, 2004 |
Effect of nosocomial bloodstream infection on the outcome of critically ill patients with acute renal failure treated with renal replacement therapy. | Pertains to hospital(s) not within the United States |
| Jarvis WR, 1996 |
Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost and prevention. | Published before 2002 |
| Kim JS, 2011 |
Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: epidemiologic and economic consequences. | Does not pertain to calculated attributable CLABSI cost estimates |
| Klevens RM, 2007 |
Estimating health care-associated infections and deaths in U.S. hospitals, 2002. | Compares and/or combines CLABSI cost estimates with other HAI |
| Kluger DM, 1999 |
The relative risk of intravascular device related bloodstream infections in adults [abstract]. | Published before 2002 |
| Landry SL, 1989 |
Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. | Published before 2002 |
| Laupland KB, 2002 |
Population based assessment of intensive care unit-acquired bloodstream infections in adults: incidence, risk factors, and associated mortality rate. | Does not pertain to calculated attributable CLABSI cost estimates |
| Laupland KB, 2006 |
Cost of intensive care unit-acquired bloodstream infections. | Pertains to hospital(s) not within the United States |
| Li J, 2001 |
Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multi-center trial. | Published before 2002 |
| Lodise TP, 2005 |
Clinical and economic impact of methicillin resistance in patients with staphylococcus aureus bacteremia. | Does not pertain to CLABSI specific HAI |
| Luce B, 1996 | Estimating costs in cost-effectiveness analysis. | Published before 2002 |
| Martin MA, 1989 |
Coagulase-negative staphylococcal bacteremia: mortality and hospital stay. | Published before 2002 |
| McCollum M, 2003 |
Cost analysis of switching from IV vancomycin to PO linezolid for the management of methicillin-resistant Staphylococcus species. | Does not pertain to calculated attributable CLABSI cost estimates |
| Meier PA, 1998 |
Impact of a dedicated intravenous therapy team on nosocomial bloodstream infection rates. | Published before 2002 |
| Mermel LA, 2000 |
Prevention of intravascular catheter-related infections. | Published before 2002 |
| Mermel LA, 2000 |
Correction: catheter related bloodstream-infections. | Published before 2002 |
| Misset B, 2004 |
A continuous quality-improvement program reduces nososcomial infection rates in the ICU. | Does not pertain to CLABSI specific HAI |
| Moran C, 2009 |
Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. | Does not pertain to calculated attributable CLABSI cost estimates |
| Morgan J, 2005 |
Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. | Does not pertain to CLABSI specific HAI |
| Mullins C, 2006 |
Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. | Does not pertain to CLABSI specific HAI |
| Nehme AE 1980 |
Nutritional support of the hosptalized patient: the team concept. | Published before 2002 |
| Nightingale CH, 1993 |
Impact of nosocomial infections on hospital costs. | Published before 2002 |
| Niven DJ, 2010 |
Cost and outcomes of nosocomial bloodstream infections complicating major traumatic injury. | Pertains to hospital(s) not within the United States |
| Nixon M, 2006 |
Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control. | Cost estimates not in U.S. dollars |
| Nosrati M, 2010 |
Excess costs associated with common healthcare-associated infections in an Iranian cardiac surgical unit. | Pertains to hospital(s) not within the United States |
| O'Grady N, 2002 |
Guidelines for the prevention of intravascular catheter-related infections. | Does not pertain to calculated attributable CLABSI cost estimates |
| Ostrowsky B, 2001 |
Reality check: should we try to detect and isolate vancomycin-resistant enterococci patients? | Published before 2002 |
| Parodi S, 2001 |
Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphyloccal species infections. | Does not pertain to calculated attributable CLABSI cost estimates |
| Pennsylvania Health Care Cost Containment Council 2005 | Hospital-acquired infections in Pennsylvania. PHC4 | Article not peer reviewed |
| Pennsylvania Health Care Cost Containment Council 2005 |
Reducing hospital-acquired infections: the business case. PHC4 | Article not peer reviewed |
| Pennsylvania Health Care CostContainment Council 2006 |
Hospital-acquired infections in Pennsylvania. PHC4 | Article not peer reviewed |
| Pirson M, 2005 |
Costs associated with hospital acquired bacteraemia in a Belgian hospital. | Pertains to hospital(s) not within the United States |
| Pittet D, 1997 |
Nosocomial bloodstream infections. | Published before 2002 |
| Plowman RP, 2001 |
The rate and cost of hospitalacquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. | Published before 2002 |
| Pronovost P, 2006 |
An intervention to decrease catheter-related bloodstream infections in the ICU. | Does not pertain to calculated attributable CLABSI cost estimates |
| Puzniak L, 2004 |
Has the epidemiology of nosocomial candidemia changed? | Does not pertain to CLABSI specific HAI |
| Rello J, 1994 |
Nosocomial acteremia in a medical-surgical intensive care unit: Epidemiologic characteristics and factors influencing mortality in 111 episodes. | Published before 2002 |
| Renaud B, 2001 |
Outcomes of primary and catheterrelated bacteremia. A cohort and case-control study in critically ill patients. | Published before 2002 |
| Rentz AM, 1998 |
The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. | Published before 2002 |
| Rubin RJ, 1999 |
The economic impact of Staphylococcus aureus infection in New York City hospitals. | Published before 2002 |
| Saint S, 2000 |
The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? | Published before 2002 |
| Salgado CD, 2003 |
Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. | Review, meta-analysis and systematic review articles |
| Sanchez-Velazquez LD, 2006 |
The burden of nosocomial infection in the intensive care unit: effects on organ failure, mortality and costs. A nested case-control study. | Pertains to hospital(s) not within the United States |
| Scheckler WE, 1980 |
Hospital costs of nosocomial infections: a prospective three month study in a community hospital. | Published before 2002 |
| Shorr AF, 2009 | Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. | Does not pertain to CLABSI specific HAI |
| Shorr AF, 2003 |
New choices for central venous catheters: potential financial implications. | Does not pertain to calculated attributable CLABSI cost estimates |
| Shorr AF, 2006 |
Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. | Does not pertain to CLABSI specific HAI |
| Slonim AD, 2001 |
Nosocomial bloodstream infection and cost. | Published before 2002 |
| Smith SD, 1996 |
Costs of nosocomial infections. | Published before 2002 |
| Song X, 2003 |
Effect of nosocomial vancomycin- resistant enterococcal bacteremia on mortality, length of stay, and costs. | Does not pertain to CLABSI specific HAI |
| Soufir L, 1999 |
Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk adjusted, cohort study. | Published before 2002 |
| Spengler RF, 1978 |
Hospital costs and mortality attributed to nosocomial bacteremias. | Published before 2002 |
| Steiner C, 2002 |
The healthcare Cost and Utilization project: an overview. | Does not pertain to calculated attributable CLABSI cost estimates |
| Stevens DL, 2002 |
Linezolid versus vancomycin for the treatment of methicillin-resistant. | Does not pertain to calculated attributable CLABSI cost estimates |
| Stone PW, 2005 |
Systematic review of economic analyses of health care-associated infections. | Review, meta-analysis and systematic review articles |
| Stone PW, 2002 |
A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990–2000. | Review, meta-analysis and systematic review articles |
| Stosor V, 1998 |
Enterococcus faecium bacteremia: does vancomycin resistance make a difference? | Published before 2002 |
| Suljagic V, 2005 |
Nosocomial bloodstream infections in ICU and non-ICU patients. | Pertains to hospital(s) not within the United States |
| Tagalakis V, 2002 |
The epidemiology of peripheral vein infusion thrombophlebitis: A critical reivew. | Does not pertain to CLABSI specific HAI |
| Tarricone R, 2010 |
Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. | Pertains to hospital(s) not within the United States |
| Taylor GJ, 1990 |
Determinants of hospital charges for coronary artery bypass surgery: the economic consequences of postoperative complications. | Published before 2002 |
| Teres D, 2002 |
Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. | Compares and/or combines CLABSI cost estimates with other HAI |
| Tomford JW, 1985 |
The IV therapy team: impact on patient care and costs of hospitalization. | Published before 2002 |
| Tompkins RG, 1992 |
Infections of Burn Wounds. 3rd ed. | Published before 2002 |
| Toufen C, 2003 |
Prevalence rates of infection in intensive care units of a tertiary teaching hospital. | Pertains to hospital(s) not within the United States |
| Turpin, RS 2011 |
Nutrition therapy cost analysis in the US pre-mixed multi-chamber bag versus compounded parenteral nutrition. | Does not pertain to calculated attributable CLABSI cost estimates |
| Umscheid CA, 2011 |
Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. | Does not pertain to calculated attributable CLABSI cost estimates |
| US Department of Health & Human Services 2008 |
Part II: Department of Health and Human Services: Centers for Medicare & Medicaid Services. 42 CFR. | Does not pertain to CLABSI specific HAI |
| Valles J, 1997 |
Nosocomial bacteremia in critically ill patients: A multicenter study evaluating epidemiology and prognosis. | Published before 2002 |
| Vincent JL 2003 |
Nosocomial infections in adult intensive –care units. | Review, meta-analysis and systematic review articles |
| Vincent J-L, 1995 |
The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study. | Published before 2002 |
| Vogel TR, 2006 |
The open abdomen in trauma. | Does not pertain to CLABSI specific HAI |
| Vrijens F, 2010 |
Hospital-acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs. | Pertains to hospital(s) not within the United States |
| Wakefield DS, 1987 |
Use of the appropriateness evaluation protocol for estimating the incremental costs associated with nosocomial infections. | Published before 2002 |
| Warren DK, 2004 |
The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. | Does not pertain to calculated attributable CLABSI cost estimates |
| Warren DK, 2004 |
Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillinresistant Staphylococcus aureus in a medical intensive care unit. | Does not pertain to calculated attributable CLABSI cost estimates |
| Waters HR, 2011 |
The business case for quality: economic analysis of the Michigan Keystone Patient Safety Program in ICUs. | Does not pertain to calculated attributable CLABSI cost estimates |
| Weinstein RA 1998 |
Nosocomial infection update. | Published before 2002 |
| Weintraub WS, 1989 |
Determinants of prolonged length of stay after coronary bypass surgery. | Published before 2002 |
| Wenzel RP 1995 |
The economics of nosocomial infections. | Published before 2002 |
| Wenzel RP, 1991 |
Feasible and desirable future targets for reducing the costs of hospital infections. | Published before 2002 |
| Wenzel RP, 2001 | The impact of hospital-acquired bloodstream infections. | Published before 2002 |
| Wey SB, 1988 |
Hospital acquired candidemia: the attributable mortality and excess length of stay. | Published before 2002 |
| Wisplinghoff H, 2003 |
Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. | Pertains to hospital(s) not within the United States |
| Wisplinghoff H, 2004 |
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. | Does not pertain to calculated attributable CLABSI cost estimates |
| Ye X, 2011 |
Economic impact of use of chlorhexidine-impregnated sponge dressing for prevention of central line-associated infections in the United States. | Does not pertain to calculated attributable CLABSI cost estimates |
| Young EM, 2006 |
Translating evidence into practice to prevent central venous catheter-associated bloodstream infections: a systems-based intervention. | Does not pertain to calculated attributable CLABSI cost estimates |
| Young LS, 2006 |
Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. | Does not pertain to CLABSI specific HAI |
| Zack JE, 2002 |
Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. | Does not pertain to calculated attributable CLABSI cost estimates |
| Zaoutis TE, 2005 |
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. | Does not pertain to CLABSI specific HAI |
